The goal of this clinical trial is to learn if daily supplementation with SPM Active® can increase omega 3 polyunsaturated fatty acid derivatives and improve well-being in adults with obesity. The main questions it aims to answer are: Does 2 g/day of SPM Active® for 12 weeks increase plasma levels of 14-hydroxydocosahexaenoic (HDHA), 17-HDHA, and 18-hydroxy eicosapentaenoic acid (HEPE)? Does 2 g/day of SPM Active® for 12 weeks improve self-reported burnout, life satisfaction, and sleep quality? Participants will: Take two SPM Active® soft-gel capsules daily for 12 weeks (±2-4 days). Provide 12-hour fasting blood samples before and after the intervention. Complete validated surveys on burnout, life satisfaction, and sleep quality at baseline and study end.
Purpose: This study aims to explore the effects of 'SPM Active®,' an omega-3 polyunsaturated fatty acid (n-3 PUFA) dietary supplement, on male adults with obesity. The supplement specifically targets the increase of monohydroxylated derivatives of n-3 PUFAs, which play a crucial role in reducing chronic, low-grade inflammation. The primary objective of the study is to determine whether administering SPM Active® at 2g/day for a longer duration (3 months) leads to higher levels of the monohydroxylated derivatives (14-HDHA, 17-HDHA, and 18-HEPE) in adults with obesity (BMI between 30 and 40 kg/m\^2, n=33). The secondary objective is to evaluate whether administration of SPM Active® improves the following outcomes: a) burnout, b) life satisfaction, and c) sleep quality. These outcomes will be assessed using validated surveys administered before and after the intervention. Participants: The study will include 33 healthy male and female participants of any ethnicity, aged 45-60 years, with a BMI of 30-40 kg/m\^2. Procedures: The intervention involves the administration of the dietary supplement 'SPM Active®' provided by Metagenics. All participants will take 2 soft gel capsules per day for 12 weeks, with a window of +/- 2-4 days. A 12-hour fasting blood sample will be collected from each participant before and after the intervention by a licensed phlebotomist at the UNC Nutrition Research Institute (NRI) at Kannapolis, NC. Additionally, participants will complete surveys at the start and end of the study.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
33
Participants will take two SPM Active® soft-gel capsules orally each day (total 2 g/day of specialized pro-resolving mediators) for 12 weeks (± 2-4 days). Capsules are provided by Metagenics and contain monohydroxylated n-3 PUFA derivatives (14-HDHA, 17-HDHA, 18-HEPE).
UNC Nutrition Research Institute
Kannapolis, North Carolina, United States
RECRUITINGChange in Plasma Levels of Monohydroxylated n-3 PUFA Derivatives (14-HDHA, 17-HDHA, 18-HEPE)
Mean change from baseline in fasting plasma concentrations of 14-HDHA, 17-HDHA, and 18-HEPE, as quantified by liquid chromatography-mass spectrometry.
Time frame: Baseline (Day 0) and End of Treatment (Week 12 ± 2-4 days)
Change in Burnout Score
The assessment of this survey is validated in a systematic review titled, "Maslach Burnout Inventory-General Survey: A Systematic Review and Meta-Analysis of Measurement Properties." This survey is measured on a scale form 0-6 where 0 is never experiencing the stated type of burnout and 6 being experiencing burnout every day. It is divided into three subscale measurements on emotional exhaustion, cynicism, and professional efficacy. High levels of burnout are indicated by high scores in emotional exhaustion and cynicism, along with low scores in professional efficacy.
Time frame: Baseline (Day 0) and End of Treatment (Week 12 ± 2-4 days)
Change in Life Satisfaction Score
The life satisfaction survey assesses global life satisfaction and its validity review is conducted by William Pavot and Ed Diener in "The satisfaction With Life Scale and the merging construct of life satisfaction." This survey is measured on a scale of 1-7 where 1 is strongly disagree and 7 is strongly agree. A low score indicates low life satisfaction, whereas a high score indicates a high level of life satisfaction.
Time frame: Baseline (Day 0) and End of Treatment (Week 12 ± 2-4 days)
Change in Sleep Quality Score
The sleep quality survey is validated by University of Pittsburgh and is detailed in "The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research." The sleep quality survey is converted to scores, where the scores range form 0-3 with a higher score being indicative of more sleep disturbances.
Time frame: Baseline (Day 0) and End of Treatment (Week 12 ± 2-4 days)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.